This guide is currently available in English. A Spanish version is in progress.
Buying Exosomes Wholesale for Connecticut Practices
ExaVeyra supplies Kimera exosome material to licensed Connecticut practices for topical aesthetic use by licensed practitioners. Please be prepared to provide the documentation needed to purchase exosomes, stem cells and other biologics that may be subject to Conn. Gen. Stat. § 21a-70 and to federal regulation under 21 CFR Part 1271. Your account is opened against the practice’s own Connecticut license and NPI, which we verify in 1 to 3 business days. Orders then ship overnight on dry ice from Florida and arrive in 1 to 3 business days, every vial is traceable to its lot, and the lot-specific Certificate of Analysis is available on request. Kiara and Vive carry public single-unit prices in our catalog, and Luxir and Luxir+ are quoted once your NPI is verified.
The registrations Connecticut requires for shipping drugs into the state are held by the shipping entities. Connecticut also limits the persons to whom a registered wholesaler may sell drugs (§ 21a-70(h)), so the documentation you provide at account setup matters. Our 503A pharmacy partner holds a Connecticut nonresident pharmacy registration, so Connecticut prescribers can also send it individual prescriptions for compounded preparations.
Two Connecticut points are worth settling early. The state’s regenerative medicine law funds and governs embryonic stem cell research rather than clinical practice, so there is no stem cell practice statute to read exosomes into or out of. And Connecticut is one of the few states with a medical spa statute: every medical spa employs or contracts with a physician, physician assistant or advanced practice registered nurse, who performs an initial in-person assessment before any cosmetic medical procedure.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Connecticut? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 12 October 2026 |
Ordering from Connecticut
ExaVeyra ships to licensed practices in all 50 states, Connecticut included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Connecticut professional license in good standing, verifiable through the Department of Public Health license lookup on eLicense.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Connecticut Sales and Use Tax Resale Certificate, issued under a sales and use tax permit, if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Connecticut registers the out-of-state supplier through the Department of Consumer Protection rather than through a board of pharmacy. Conn. Gen. Stat. § 21a-70 defines a wholesaler as a person within or outside the state who supplies drugs, devices or cosmetics to prescribing practitioners, pharmacies, hospitals, clinics and others, and requires a certificate of registration, renewed annually, with a separate certificate for each location outside Connecticut that distributes products into the state. The Drug Control Division describes the out-of-state registration as covering controlled substances, legend and over-the-counter drugs, medical devices and cosmetics, with home-state licensure supplied at application. Subsection (h) of the same section lists the purchasers to whom a registered wholesaler may sell drugs, and the supplier answers for that list. Separately, § 20-627 requires a pharmacy outside Connecticut that ships legend drugs or devices into the state on a prescription to be registered on approval of the Commission of Pharmacy, to hold a valid home-state license and to submit its most recent inspection report, which for sterile compounded products addresses USP Chapter 797. Each registration sits with the supplier, not with the purchasing practice.
Conn. Gen. Stat. §§ 21a-70, 20-627 · Connecticut Department of Consumer Protection, Drug Control Division
Connecticut regenerative-medicine law
Connecticut has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Connecticut legislated on regenerative medicine in 2005, and the law is easy to mistake for a practice statute. Public Act 05-149, first codified at §§ 19a-32d to 19a-32g and now at §§ 32-41jj to 32-41mm, defines regenerative medicine as the process of creating living, functional tissue to repair or replace lost tissue or organ function, prohibits human reproductive cloning, sets consent and oversight rules for embryonic stem cell research, and establishes the Regenerative Medicine Research Fund, which awards grants to eligible research institutions. It regulates research and its funding rather than the services a practice offers, so a Connecticut practice finds its working rules in the medical spa statute, § 19a-903c, and in the medicine, physician assistant and nursing chapters of title 20.
How this applies to exosomes
Connecticut’s regenerative medicine law concerns research, embryonic stem cells and a grant fund, and it does not address clinical products of any kind, so there is no state definition to read exosomes into or out of. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. The state-level questions a Connecticut practice actually works through are who staffs and assesses at a medical spa under § 19a-903c, and who may perform which procedure under the medical, physician assistant and nursing statutes. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with lot documentation and a Certificate of Analysis for every lot, available on request.
Who can handle product in a Connecticut practice
Connecticut gives a practice two workable models. A physician-led practice delegates to physician assistants under written delegation agreements and directs nurses through orders. An APRN who has completed the three-year, 2,000-hour collaboration period can lead within nursing scope without a physician. At a medical spa, either model works so long as the spa employs or contracts with a qualifying physician, physician assistant or APRN, posts the names and specialties of those performing procedures, and keeps procedures with that clinician or a registered nurse.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed under chapter 370 perform medical acts within their scope and are the source of delegation to physician assistants and, through orders, to nurses. A physician may also be the clinician a medical spa employs or contracts with under § 19a-903c, provided they actively practice in Connecticut and have training and experience in cosmetic medical procedures. |
| NP / APRN | For the first three years after licensure, an advanced practice registered nurse practices in a written collaboration with a Connecticut physician under § 20-87a(b)(2). After at least three years and 2,000 hours of collaboration, § 20-87a(b)(3) allows the APRN to diagnose, treat and prescribe alone or in collaboration, after giving written notice to the Commissioner of Public Health, and the Department of Public Health publishes a list of APRNs practicing not in collaboration with a physician. |
| PA | Physician assistants practice under a clearly identified supervising physician who keeps final responsibility for patient care, under § 20-12c, and perform medical functions delegated under a written delegation agreement, under § 20-12d. Supervision must be active and direct, though the statute does not fix a number of physician assistants per physician. |
| RN | Under § 20-87a(a), a registered nurse executes the medical regimen under the direction of a licensed physician, dentist or advanced practice registered nurse, and may also execute orders issued by a physician assistant within both scopes. At a medical spa, § 19a-903c adds that cosmetic medical procedures may be performed only by the qualifying physician, physician assistant or APRN, or by a registered nurse, so other staff are outside that group. |
Good faith examination
At a medical spa, § 19a-903c(c) sets the rule directly: a physician, physician assistant or APRN employed by or under contract with the spa performs an initial in-person physical assessment of each person before a cosmetic medical procedure is performed. The in-person wording was added by Public Act 15-242. Outside a medical spa, the scope statutes do the same work, since the practitioner who may diagnose and prescribe evaluates the patient and issues the order that a registered nurse then carries out. Confirm current expectations with the Department of Public Health and the relevant board.
Ownership and clinic licensing
Connecticut shapes practice ownership through its entity statutes. Under the professional corporation chapter, Conn. Gen. Stat. §§ 33-182c and 33-182g, only persons licensed to render the same professional service may organize and hold shares in a professional corporation, and stock may not be issued or transferred to anyone else. The medical foundations law of 2009, chapter 594b, was enacted to give nonprofit hospitals, health systems and medical schools a vehicle for practicing medicine through licensed employees, which the Office of Legislative Research describes as providing more flexibility for hospitals seeking to employ physicians directly. A medical spa itself must employ or contract with a qualifying physician, physician assistant or advanced practice registered nurse under § 19a-903c. Structure the entity, and any management services arrangement, with Connecticut counsel before opening.
Cold chain into Connecticut
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Connecticut order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Greenwich | Fairfield | Concierge and aesthetic practices along the New York border. |
| Stamford | Fairfield | Largest Fairfield County city, with a broad dermatology and aesthetic mix. |
| Westport | Fairfield | Coastal med spa and concierge market in central Fairfield County. |
| New Haven | New Haven | Clinical and research-adjacent practices around the university and hospital corridor. |
| Hartford | Hartford | Capital region hub, home to the state agencies that license practices. |
| West Hartford | Hartford | Suburban aesthetic market served alongside Hartford. |
- Connecticut orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
Wholesale exosome supply by city in Connecticut
Each city page covers local receiving conditions, delivery disruptions and business licence rules for Connecticut practices in that area.
Practice types we supply in Connecticut
Federal and Connecticut rules for an order
- Federal
- Ningún producto de exosomas está aprobado por la FDA, como indica la notificación pública de seguridad de la FDA sobre productos de exosomas. ExaVeyra suministra material de exosomas para uso estético tópico por profesionales con licencia.
- Las preparaciones magistrales se rigen por la sección 503A de la Ley Federal de Alimentos, Medicamentos y Cosméticos (21 U.S.C. 353a), que exige una prescripción para un paciente individual.
- Connecticut
- Connecticut’s medical spa statute, § 19a-903c, requires every medical spa to employ or contract with a physician, physician assistant or APRN who performs an initial in-person assessment before a cosmetic medical procedure.
- Physician assistants practice under a supervising physician and a written delegation agreement (§§ 20-12c and 20-12d), and an APRN may practice without physician collaboration after three years and 2,000 hours (§ 20-87a).
- Practitioner licenses are confirmed through the Department of Public Health license lookup on eLicense before a first order ships.
Connecticut licensing and verification
Connecticut Medical Examining Board
Hears physician and physician assistant matters, supported by the Department of Public Health.
Connecticut Board of Examiners for Nursing
Oversees RN, LPN and APRN practice.
Department of Public Health, APRNs practicing not in collaboration with a physician
The published roster of APRNs who have completed the collaboration period under § 20-87a.
Department of Consumer Protection, nonresident pharmacy registration
Registers pharmacies outside Connecticut under § 20-627 after Commission of Pharmacy review.
Department of Consumer Protection, Drug Control Division
Registers out-of-state wholesalers of drugs, devices and cosmetics under § 21a-70.
Connecticut sourcing questions
- Can a Connecticut clinic buy exosomes wholesale?
- A licensed Connecticut practice can apply for an ExaVeyra practice account for Kimera exosome material, supplied for topical aesthetic use by licensed practitioners. Please be prepared to provide the documentation needed to purchase exosomes, stem cells and other biologics that may be subject to Conn. Gen. Stat. § 21a-70 and to federal regulation under 21 CFR Part 1271. Section 21a-70(h) limits the persons to whom a registered wholesaler may sell drugs, and the account is verified against the practice’s license and NPI in 1 to 3 business days.
- What are the steps to open a Connecticut practice account?
- Submit the online application with the practice’s Connecticut license, NPI and delivery address, and sign the professional-use acknowledgment for exosome material; a practice buying for resale adds its Connecticut resale certificate. We check the license and NPI in 1 to 3 business days, and once the account is live an order ships overnight on dry ice from Florida and arrives in 1 to 3 business days.
- How do Connecticut practices see exosome pricing?
- Single-unit prices for Kiara and Vive are published in the ExaVeyra catalog. Luxir and Luxir+ are quoted individually, and once a practice’s NPI is verified its account shows wholesale pricing across the full range.
- Does Connecticut have a stem cell law that covers exosomes?
- No. Connecticut’s regenerative medicine law, now at §§ 32-41jj to 32-41mm, governs embryonic stem cell research, prohibits human reproductive cloning and funds research grants through the Regenerative Medicine Research Fund. It does not regulate clinical products or services in a practice. Exosome products are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- What does Connecticut’s medical spa law require?
- Section 19a-903c requires each medical spa to employ or contract with a physician, physician assistant or APRN who actively practices in Connecticut and has training and experience in cosmetic medical procedures. That clinician performs an initial in-person physical assessment before a cosmetic medical procedure, procedures are performed only by that clinician or a registered nurse, and the spa posts the names and specialties of those performing procedures on site, on its website and in a written notice given before the procedure.
- Can my Connecticut practice source 503A compounded peptides through ExaVeyra?
- Yes. Compounded formulations are prepared by our 503A pharmacy partner, a compounding pharmacy licensed by the Texas State Board of Pharmacy, and it holds the Connecticut nonresident pharmacy registration that § 20-627 requires of a pharmacy outside the state shipping legend drugs into Connecticut on a prescription. That registration is issued on approval of the Commission of Pharmacy and sits with the pharmacy rather than with your practice, so Connecticut prescribers send it individual prescriptions, and we confirm current status for your destination before the first prescription is placed.
- Can an APRN lead a Connecticut practice without a physician?
- After the collaboration period, yes. Under § 20-87a an APRN practices in a written collaboration with a Connecticut physician for the first three years of licensure, and after at least three years and 2,000 hours of collaboration may practice alone after giving notice to the Commissioner of Public Health. At a medical spa, an APRN can be the required clinician under § 19a-903c. Physician assistants, by contrast, always practice under a supervising physician.
- Does my Connecticut clinic need a wholesale registration to buy exosomes?
- No. The out-of-state wholesaler registration under § 21a-70 and the nonresident pharmacy registration under § 20-627 are held by the entities shipping into Connecticut, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Connecticut?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 12 October 2026 by Benn Bluestein-Veyra, M.Sc. Organic Chemistry. Every claim above links to a primary source.
- 21 CFR Part 1271, human cells, tissues, and cellular and tissue-based products (accessed 13 October 2026)
- Conn. Gen. Stat. § 21a-70, registration of manufacturers and wholesalers of drugs (2026 Supplement) (accessed 12 October 2026)
- Conn. Gen. Stat. § 20-627, nonresident pharmacy registration (2026 Supplement, as amended by P.A. 25-101) (accessed 12 October 2026)
- CT Department of Consumer Protection, wholesaler of drugs, medical devices and/or cosmetics outside of Connecticut (accessed 12 October 2026)
- CT Department of Consumer Protection, pharmacy license outside the State of Connecticut (accessed 12 October 2026)
- Conn. Gen. Stat. §§ 32-41jj to 32-41mm (formerly §§ 19a-32d to 19a-32g), regenerative medicine research (accessed 12 October 2026)
- Conn. Gen. Stat. § 19a-903c, medical spas (P.A. 14-119, as amended by P.A. 15-242) (accessed 12 October 2026)
- Public Act 14-119, An Act Concerning the Department of Public Health’s Recommendations Concerning Medical Spas (accessed 12 October 2026)
- Office of Legislative Research, Medical Spas, report 2025-R-0159 (accessed 12 October 2026)
- Conn. Gen. Stat. § 20-87a, nursing and advanced nursing practice: scope (accessed 12 October 2026)
- Conn. Gen. Stat. §§ 20-12c and 20-12d, physician assistants (accessed 12 October 2026)
- Conn. Gen. Stat. ch. 594a, professional service corporations (§§ 33-182c, 33-182g) (accessed 12 October 2026)
- Conn. Gen. Stat. ch. 594b, medical foundations (§ 33-182bb) (accessed 12 October 2026)
- Office of Legislative Research, Medical Foundations, report 2013-R-0262 (accessed 12 October 2026)
- CT Department of Public Health, APRNs practicing not in collaboration with a licensed physician (accessed 12 October 2026)
- Connecticut Medical Examining Board (accessed 12 October 2026)
- Connecticut Board of Examiners for Nursing (accessed 12 October 2026)
- CT Department of Revenue Services, IP 2009(15), resale certificates (accessed 12 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 12 October 2026)
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.